Payment overview · 2025
General Payments
$255.15
10 reported records · 7 companies
Healthcare provider profile · identity verified
Christopher Dean Averett Marshall, MD
Allopathic & Osteopathic Physicians|Family Medicine|Addiction Medicine · PARSONS, TN · NPI 1144425075
Verified facts
What the public records show
CMS Open Payments records show Christopher Dean Averett Marshall, MD received $255.15 in general payments during 2025 across 10 reported records.
DePuy Synthes Sales Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $62.45 | 24.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.31 | 20.5% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $37.05 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.10 | 12.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.71 | 11.6% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $23.91 | 9.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.62 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.15 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NA Normalized: na |
Device | DePuy Synthes Sales Inc. | $62.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.31 | 2 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 76 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 230 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 61 |
| Gabapentin | Gabapentin | 172 | 41 |
| Lisinopril | Lisinopril | 165 | 61 |
| Omeprazole | Omeprazole | 163 | 60 |
| Prednisone | Prednisone | 150 | 93 |
| Furosemide | Furosemide | 132 | 46 |
| Potassium Chloride | Potassium Chloride | 128 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 38 |
| Trazodone Hcl | Trazodone Hcl | 112 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 39 |
| Clonazepam | Clonazepam | 107 | 18 |
| Ozempic | Semaglutide | 104 | 19 |
| Mounjaro | Tirzepatide | 103 | 24 |
| Donepezil Hcl | Donepezil Hcl | 102 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 31 |
| Losartan Potassium | Losartan Potassium | 98 | 31 |
| Simvastatin | Simvastatin | 98 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 35 |
| Memantine Hcl | Memantine Hcl | 89 | 25 |
| Tramadol Hcl | Tramadol Hcl | 87 | 27 |
| Allopurinol | Allopurinol | 84 | 32 |
| Meloxicam | Meloxicam | 82 | 36 |
| Spironolactone | Spironolactone | 80 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 24 |
| Progesterone | Progesterone, Micronized | 76 | 20 |
| Pregabalin | Pregabalin | 72 | 22 |
| Azithromycin | Azithromycin | 69 | 56 |
| Famotidine | Famotidine | 65 | 24 |
| Glimepiride | Glimepiride | 65 | 20 |
| Eliquis | Apixaban | 64 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 64 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 32 |
| Jardiance | Empagliflozin | 60 | 17 |
| Cephalexin | Cephalexin | 56 | 36 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 38 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 16 |
| Montelukast Sodium | Montelukast Sodium | 51 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 17 |
| Alprazolam | Alprazolam | 49 | 13 |
| Clonidine Hcl | Clonidine Hcl | 49 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 43 | 19 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 11 |
| Fluconazole | Fluconazole | 40 | 20 |
| Buspirone Hcl | Buspirone Hcl | 38 | 17 |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Bumetanide | Bumetanide | 37 | 15 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | 16 |
| Primidone | Primidone | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 14 |
| Celecoxib | Celecoxib | 35 | 16 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 25 |
| Atenolol | Atenolol | 31 | 11 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Valsartan | Valsartan | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.15 · 10 records | DePuy Synthes Sales Inc. | BRIXADI, CAPLYTA, FARXIGA, MOUNJARO, NA, VARIAX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error